JP2022549066A - 疾患の処置のための方法および組成物 - Google Patents

疾患の処置のための方法および組成物 Download PDF

Info

Publication number
JP2022549066A
JP2022549066A JP2022512736A JP2022512736A JP2022549066A JP 2022549066 A JP2022549066 A JP 2022549066A JP 2022512736 A JP2022512736 A JP 2022512736A JP 2022512736 A JP2022512736 A JP 2022512736A JP 2022549066 A JP2022549066 A JP 2022549066A
Authority
JP
Japan
Prior art keywords
cxcr2
at1r
angii
cxcl8
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022512736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549066A5 (https=
Inventor
ロバート ピアソン シェパード，
ケヴィン ドナルド ジョージ プレーガー，
Original Assignee
ダイメリックス バイオサイエンス ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019903606A external-priority patent/AU2019903606A0/en
Application filed by ダイメリックス バイオサイエンス ピーティーワイ リミテッド filed Critical ダイメリックス バイオサイエンス ピーティーワイ リミテッド
Publication of JP2022549066A publication Critical patent/JP2022549066A/ja
Publication of JP2022549066A5 publication Critical patent/JP2022549066A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022512736A 2019-09-26 2020-09-18 疾患の処置のための方法および組成物 Pending JP2022549066A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019903606A AU2019903606A0 (en) 2019-09-26 Method and Compositions for the Treatment of Disease
AU2019903606 2019-09-26
PCT/AU2020/050987 WO2021056051A1 (en) 2019-09-26 2020-09-18 Method and composition for the treatment of disease

Publications (2)

Publication Number Publication Date
JP2022549066A true JP2022549066A (ja) 2022-11-24
JP2022549066A5 JP2022549066A5 (https=) 2023-09-01

Family

ID=75164804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022512736A Pending JP2022549066A (ja) 2019-09-26 2020-09-18 疾患の処置のための方法および組成物

Country Status (8)

Country Link
US (1) US20240009191A1 (https=)
EP (1) EP4034109A4 (https=)
JP (1) JP2022549066A (https=)
KR (1) KR20220070435A (https=)
CN (1) CN114466653A (https=)
AU (1) AU2020351826A1 (https=)
CA (1) CA3152115A1 (https=)
WO (1) WO2021056051A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230165838A1 (en) * 2020-05-06 2023-06-01 Dimerix Bioscience Ltd. Treatment for acute respiratory distress syndrome
WO2021222971A1 (en) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Treatment for virus induced acute respiratory distress syndrome
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2252327A2 (en) * 2007-12-04 2010-11-24 Schering Corporation Methods of treating copd
US20120100130A1 (en) * 2009-03-27 2012-04-26 Dimerix Bioscience Pty Ltd. Novel Receptor Hetero-Dimers/-Oligomers
CN107899012A (zh) * 2011-01-11 2018-04-13 戴麦里克斯生物科学有限公司 联合疗法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANDREAS, S. ET AL.: "Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial", THE EUROPEAN RESPIRATORY JOURNAL, vol. 27, no. 5, JPN6024035583, 2006, pages 972 - 979, XP093080411, ISSN: 0005536682, DOI: 10.1183/09031936.06.00098105 *
CHAPMAN, R. W. ET AL.: "CXCR2 antagonists for the treatment of pulmonary disease", PHARMACOLOGY & THERAPEUTICS, vol. 121, no. 1, JPN6024035585, 2009, pages 55 - 68, XP025816759, ISSN: 0005536684, DOI: 10.1016/j.pharmthera.2008.10.005 *
KIM, H. Y. ET AL.: "Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypert", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 34, no. 1, JPN6024035582, 2011, pages 120 - 127, ISSN: 0005536681 *
KIRSTEN, A. M. ET AL.: "The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate", PULMONARY PHARMACOLOGY & THERAPEUTICS, vol. 31, JPN6024035587, 2015, pages 36 - 41, XP093080408, ISSN: 0005536687, DOI: 10.1016/j.pupt.2015.02.001 *
LAZAAR, A. L. ET AL.: "Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD", THE EUROPEAN RESPIRATORY JOURNAL, vol. 52, no. 4, JPN6024035586, 2018, pages 1801020, ISSN: 0005536685 *
RENNARD, S. I. ET AL.: "CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 191, no. 9, JPN6024035588, 2015, pages 1001 - 1011, XP093080406, ISSN: 0005536686, DOI: 10.1164/rccm.201405-0992OC *
三嶋 理晃: "COPDの病型分類と薬物治療の進歩", 日本内科学会雑誌, vol. 第99巻, 第9号, JPN6024035584, 2010, pages 2302 - 2308, ISSN: 0005536683 *

Also Published As

Publication number Publication date
CN114466653A (zh) 2022-05-10
AU2020351826A1 (en) 2022-03-10
KR20220070435A (ko) 2022-05-31
CA3152115A1 (en) 2021-04-01
EP4034109A4 (en) 2023-10-18
WO2021056051A1 (en) 2021-04-01
EP4034109A1 (en) 2022-08-03
US20240009191A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
US12083102B2 (en) Method for treating inflammatory disorders
JP2022549066A (ja) 疾患の処置のための方法および組成物
US20240173302A1 (en) Treatment of inflammatory diseases
US20230165838A1 (en) Treatment for acute respiratory distress syndrome
CN103655607B (zh) 一种含有奥美拉唑的药物组合物
WO2024026528A1 (en) Dosage regimen for the treatment of copd
WO2024234031A1 (en) Therapeutic formulations for kidney disease comprising repagermanium or propagermanium and/or at1 r blockers
ES2770785T3 (es) Terapia de combinación
WO2010003170A1 (en) Novel receptor hetero-dimers/-oligomers
JP2009511457A (ja) ナトリウムホメオスタシス、高血圧症、およびアルドステロン症を治療するための、プリン作動性シグナル伝達経路のモジュレーター
WO2010031114A1 (en) Novel receptor hetero-dimers/-oligomers
HK1192712B (en) Combination therapy
HK1192712A (en) Combination therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250226